

- 1 **Galectin antagonist use in mild cases of SARS-CoV-2; pilot feasibility**
- 2 **randomised, open label, controlled trial.**

3 **Authors:**

4

5 Dr Alben Sigamani\*

6 \*Corresponding Author

7 alben.sigamani.dr@narayanahealth.org

8 Group Head, Clinical Research, Narayana Health, Bangalore

9

10 Dr Samarth Shetty

11 Consultant, Mazumdar Shaw Medical Center, Narayana Health, Bangalore

12

13 Dr Madhavi

14 Consultant, Mazumdar Shaw Medical Center, Narayana Health, Bangalore

15

16 Miss Mathu Ruthra

17 Department of Clinical Research, Narayana Health Bangalore

18

19 Miss Sudhishma

20 Department of Clinical Research, Narayana Health Bangalore

21

22 Mr Anup Chugani

23 MedGenome Laboratories

24

25 Dr Hana Chen-Walden

26 Medical Officer, Pharmalectin Inc

27

28 Mr ThomasKutty BS-CCP

29 Clinical Perfusionist Baylor Scott& White Health

30 thomaskutty.alumparambil@bswhealth.org

31

32 Dr David Platt

33 Chief Chemist, Pharmalectin Inc

34

35

36 **Word count: 2522 – only manuscript**

37 **2972 – with abstract**

38

39 **Abstract**

40 **Importance**

41 Novel SARS-CoV-2 virus has infected nearly half a billion people across the world and is  
42 highly contagious. There is a need for a novel mechanism to block viral entry and stop its  
43 replication.

44 **Background**

45 Spike protein N terminal domain (NTD) of the novel SARS-CoV-2 is essential for viral entry  
46 and replication in human cell. Thus the S1 NTD of human coronavirus family, which is  
47 similar to a galectin binding site - human galactose binding lectins, is a potential novel target  
48 for early treatment in COVID-19.

49 **Objectives**

50 To study the feasibility of performing a definitive trial of using galectin antagonist –  
51 Prolectin-M as treatment for mild, symptomatic, rRT-PCR positive, COVID-19.

52 **Main outcomes and measures**

53 Cycle threshold (Ct) value is number of cycles needed to express fluorescence, on real time  
54 reverse transcriptase polymerase chain reaction. Ct values expressed for RNA polymerase  
55 (Rd/RP) gene +Nucleocapsid gene and the small envelope (E) genes determine infectivity of  
56 the individual. A digital droplet PCR based estimation of the Nucleocapsid genes (N1+N2) in  
57 absolute copies/ $\mu$ L determines active viral replication.

58 **Design and intervention**

59 Pilot Feasibility Randomised Controlled Open-Label, parallel arm, study. Oral tablets of  
60 Prolectin-M were administered along with the best practice, Standard of Care (SoC) and  
61 compared against SoC. Voluntarily, consenting individuals, age >18 years, and able to  
62 provide frequent nasopharyngeal and oropharyngeal swabs were randomly allocated by  
63 REDCap software.

64 The intervention, Prolectin-M was administered as a multi dose regime of 4 gram tablets.  
65 Each tablet contained 2 grams of (1-6)-Alpha-D-mannopyranosil mixed with 2 grams of  
66 dietary fibre. Each participant took a single chewable tablet every hour, to a maximum of 10  
67 hours in a day. Tablets were administered only during the daytime, for total of 5 days.

## 68 **Results**

69 This pilot trial demonstrated the feasibility to recruit and randomize participants. By day 7,  
70 following treatment with Prolectin-M, Ct value of Rd/Rp + N gene increased by 16.41 points,  
71 95% (CI – 0.3527 to 32.48, p=0.047). Similarly, small envelope (E) gene also increased by  
72 17.75 points (95% CI;-0.1321 to 35.63, p = 0.05). The expression of N1, N2 genes went  
73 below detectable thresholds by day 3 (Mann Whitney U = 0.000, p<0.029).  
74 rRT-PCR testing done in the clinic on day 1, 7, and 14 had 3 participants (60%) turn negative  
75 by day 7 and all turned negative by day 14 and stayed negative until day 28. In the SoC group  
76 2 participants had zero detectable viral loads at baseline, 2 participants tested negative on day  
77 14, and the last participant tested remained positive on day 28. There were no serious  
78 adverse events, and all participants were clinically asymptomatic before day 28 with reactive  
79 immunoglobulin G (IgG).

## 80 **Trial relevance**

81 This pilot study proves that it is feasible and safe to perform a trial using a Galectin  
82 antagonist in COVID-19. This is a novel mechanism for blocking viral entry and its  
83 subsequent replication.

## 84 **Trial Registration**

85 Clinical Trials.gov identifier NCT04512027; CTRI ref. CTRI/2020/09/027833

86

87

## 88 **Introduction**

89 SARS-CoV-2 has infected over 40 million people worldwide and is responsible for over 1.1  
90 million deaths.<sup>1</sup> Several treatments have been authorized by regulators around the globe and  
91 none of them have been able to lower its infectivity.<sup>2</sup> SARS-CoV-2, a new member of the  
92 coronaviruses known to infect humans,<sup>3</sup> is a single-stranded RNA-enveloped virus, with a  
93 large number of glycosylated S proteins covering its surface.<sup>4</sup> These proteins mediate viral  
94 cell entry following a S protein binding on host cell surface.<sup>5</sup>

95 During viral infection, the target cells activate the S protein, by cleaving it into S1 and S2  
96 subunits.<sup>6</sup> The S1 subunit is further divided into a N-terminal domain (NTD) and a C-  
97 terminal domain (CTD). The CTD is known to bind the human angiotensin converting  
98 enzyme-2 (ACE-2) receptors while NTD seeks gangliosides on cell surface to stabilize cell  
99 adhesion.<sup>7,8</sup>

100 SARS-CoV-2 belong to betacoronaviridae family, which includes mouse hepatitis  
101 coronavirus (MHV). The S1-NTD structure, described in the mouse hepatitis coronavirus  
102 (MHV), demonstrates a similar structural fold as the human galactose binding lectins  
103 (galectins).<sup>9</sup> Galectins are carbohydrate-binding proteins, involved in many physiological  
104 functions, such as inflammation, immune responses, cell migration, autophagy and  
105 signalling.<sup>10</sup> They are also involved immunogenicity, i.e. cell recognition, between human  
106 cells and infective pathogens; viruses, bacteria, and parasites.<sup>11</sup>

107 Prolectin – M is an orally administered polysaccharide. Polysaccharides competitively bind  
108 to the N-terminal tail of human galectin-3 through a proline isomerization.<sup>12</sup> Galectin-3 (Gal-  
109 3) is 1 among the 15 galectins described in humans and also a ubiquitous human galectin  
110 expressed in various disease pathogenesis pathways.<sup>13,14</sup> The objective of this trial is to  
111 demonstrate the feasibility of a large randomised controlled clinical trial, and a possible  
112 mechanism of action for galectin antagonists as treatment in COVID-19.

113 Viral culture studies of SARS-CoV-2<sup>15</sup> indicate, that date of onset of symptoms and cycle  
114 threshold levels relate to infectivity; a cycle threshold of <25 is considered to be infectious.<sup>16</sup>

115 <sup>17</sup> A cycle threshold (Ct) value is the number of replication cycles required for a signal of  
116 reverse transcription polymerase chain reaction (rRT-PCR) product, to cross a determined  
117 threshold.

118 Most rRT-PCR approved kits, report Ct values for the RNA dependent RNA polymerase  
119 (Rd/Rp), envelope (E) protein and nucleocapsid genes. All three genes are reported together  
120 for higher sensitivity. The droplet digital PCR measures expression of only nucleocapsid  
121 genes (N1&N2) as an absolute number in copies/uL.<sup>18</sup> We hypothesized that blocking S1  
122 NTD using a galectin antagonist can affect viral replication in nasopharyngeal,  
123 oropharyngeal, gastrointestinal tract, and potentially clear the virus from the person to make  
124 them non-infectious in a shorter time.<sup>19</sup>

125 For this pilot study we considered a rising number in the Ct values, along with a reduction in  
126 the number of copies/ $\mu$ L of the nucleocapsid gene as a measure of our endpoint. However, in  
127 future clinical trials Prolectin-M should be tested using an endpoint that measures the effect  
128 on time to recovery in days as well as the reduction of infectivity.<sup>20,21</sup> A galectin antagonist  
129 could treat COVID-19 patients early in the disease pathogenesis and prevent spread of  
130 SARS-CoV-2 within the community.<sup>22</sup>

## 131 **Methods**

### 132 **Trial Design and oversight**

133 This investigation is a pilot and feasibility open-label randomized controlled trial. The trial  
134 protocol appears in supplement 1. A total of 10 subjects were identified between September  
135 15<sup>th</sup> and 19<sup>th</sup>, 2020. Study data was collected and managed using REDCap electronic data  
136 capture tools hosted at [Narayana Hrudayalaya Limited Bangalore].<sup>23,24</sup>

137 REDCap (Research Electronic Data Capture) is a secure, web-based software platform  
138 designed to support data capture for research studies, providing 1) an intuitive interface for  
139 validated data capture; 2) audit trails for tracking data manipulation and export procedures; 3)  
140 automated export procedures for seamless data downloads to common statistical packages;  
141 and 4) procedures for data integration and interoperability with external sources.

142 This study followed the Consolidated Standards of Reporting Trials (CONSORT) 2010  
143 extension to randomized pilot and feasibility trials.<sup>25</sup> The study was registered at  
144 [clinicaltrials.gov](https://clinicaltrials.gov) (NCT04512027) and the Clinical Trials Registry of India  
145 (CTRI/2020/09/027833). Study protocol and all documents were reviewed by Institutional  
146 Ethics Committee – Narayana Health and approved (NHMEC Ref. No. S44/ 2020), on 31<sup>st</sup> of  
147 August 2020. The study was conducted in compliance with the Declaration of Helsinki, the  
148 Good Clinical Practice guidelines, and local regulatory requirements.

149 Before enrolment and allocation to the study arms, informed consent for participation in the  
150 study was obtained in writing from all participants. The participant also signed a form,  
151 declaring that they received the correct information and gave informed consent for voluntary  
152 participation in the trial, before being randomized.

### 153 **Participants**

154 This single center trial enrolled hospitalized, eligible, and consenting participants between the  
155 ages of 18 and 45. All patients had to have an instrumental diagnosis for COVID-19; a  
156 positive rRT-PCR for SARS-CoV-2 obtained from an outpatient collection of  
157 nasopharyngeal swabs. Other inclusion criteria were the presence of symptoms that were not  
158 older than 72 hours and an ability to provide consent to undergo repeated collection of throat  
159 and nasal swabs over the 7-day period. Samples were collected pre randomization, during  
160 drug administration on days 3 and 5 and 7.

161 Exclusion criteria included oxygen saturation at admission  $\leq 96\%$ , high temperature  $\geq 100^{\circ}$  F  
162 ( $\geq 37.5^{\circ}$ C) not controlled on oral doses of acetaminophen, known history of diabetes on oral  
163 medications or insulin therapy or interleukin-6 levels  $\geq 3$  times of laboratory reference range  
164 and / or significantly elevated levels of CRP, serum ferritin or d-dimer or a Lymphocyte /  
165 monocyte ratio  $\leq 3$  or neutrophil / lymphocyte ratio  $\geq 5$  or platelet count  $\leq 150,000$  cells per  
166 microliter. Previously tested positive and recovered for SARS-CoV-2. Also participants on  
167 any chronic medications for more than 4 weeks before randomization or active malignancy or  
168 having any co-morbidity that increases risk of rapid disease progression were excluded.

### 169 **Objectives**

170 The primary aim was to evaluate the efficacy, safety and feasibility of administering  
171 Prolectin-M versus the SoC for 5 days. The primary endpoint was a change in absolute count  
172 of Nucleocapsid gene and a rising Ct value, estimated from serial samples of RNA extracted  
173 from a nasopharyngeal swab. The swab was collected in all participants on days 1 (day of  
174 randomisation), 3, 5, and 7. Clinical progression was estimated on a 7-point scale recorded on  
175 days 7, 21, and 28. A 2-point change was defined as clinical progression.

176 7-point severity score (ordinal scale):

- 177 1. Not hospitalized, no limitations on activities
- 178 2. Not hospitalized, limitation on activities.
- 179 3. Hospitalized, not requiring supplemental oxygen.
- 180 4. Hospitalized, requiring supplemental oxygen.
- 181 5. Hospitalized, on non-invasive ventilation or high flow oxygen devices.
- 182 6. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane  
183 oxygenation (ECMO).
- 184 7. Death

### 185 **Randomization and Treatments**

186 Participants were randomly assigned in a 1:1 ratio to receive a 4 gram tablet of Prolectin-M; a  
187 (1-6)-Alpha-D-Mannopyranose, and SoC (Treatment group) or SoC (Control group) via a  
188 web-based secure centralized system (REDCap). An independent statistician provided a



189 computer-generated assignment randomization list and blocked with varying block sizes  
190 unknown to the investigators.  
191 Prolectin-M was administered orally once every hour up to a maximum dose through the day  
192 of 40 grams or 10 tablets a day. The intention was to mimic the viral replication cycle of 8 –  
193 10 hours<sup>26</sup> and also to ensure that the participant is consuming the tablets during the day  
194 under supervision of a research nurse. Each subject was encouraged to keep the tablet in their  
195 mouth for 1- 2 minutes before it dissolved and swallowed. During a mealtime, breakfast,  
196 lunch, tea, and dinner, the subject had to wait for 30 minutes after the last meal before taking  
197 the next tablet. This was to avoid any potential drop in blood glucose as the tablets could  
198 block absorption of carbohydrates consumed in the meal.

#### 199 **Procedures**

200 Patient follow up was maintained for 28 days from the day of randomisation. A sample was  
201 considered negative when no Ct value was determined, and no amplification curve was  
202 observed or if the Ct value was >29 for all three targets.

203 A nasopharyngeal / oropharyngeal swab was transported to the research laboratory for RNA  
204 extraction in a viral transport media (#MG20VTM-3, MagGenome). All RNA extractions  
205 were carried out using the QIAamp Viral RNA mini kit (# 52904, Qiagen) following the  
206 standard instructions as per the kit protocol.

207 For each blinded sample the Ct value for Rd/Rp and N, E gene, genes were reported.

208 **rRT PCR:** The extracted RNA was analysed on a rRT PCR platform: TRUPCR® SARS-  
209 CoV-2 RT qPCR KITV2 (#3B3043B BlackBio Biotech) SARS-CoV-2. To determine the  
210 efficiency of the PCR, Ct values obtained from a series of 5 template DNA dilutions of at  
211 least 3 different samples were graphed on the y-axis versus the log of the dilution on the x-  
212 axis. □The Ct values assumed by the following equation were employed to calculate the

213 logarithm of the recombinant gene copy numbers from:  $Ct = \text{slope} \times \log(\text{Gene}$   
214  $\text{Copy Number}) + 1$  where I in the formula acts as the intercept of standard curve.<sup>27</sup>

215 **Droplet Digital PCR (ddPCR):** The RNA was also analysed on the  
216 Droplet Digital PCR (BioRad, USA). This platform is FDA approved for emergency use  
217 authorization in COVID-19.<sup>18</sup> The test is a partition-based endpoint single well RT-PCR test.  
218 The ddPCR was combined with rRT PCR because of its higher sensitivity and precision in  
219 low viral abundance samples and for the ability to provide absolute copy numbers and any  
220 resistance to inhibition often seen in rRT-PCR testing.

221 The analytic sensitivity was calculated as 0.260 cp/ $\mu$ l to 0.351 cp/ $\mu$ l (cp = copies) for genetic  
222 markers, SARS-CoV-2 N1 and N2 genes, and an internal control human RPP30  
223 gene. The laboratory remained blind to treatment allocation throughout the analysis. On day  
224 28, all participants were tested for serum antibodies against SARS-CoV-2 Immunoglobulin G  
225 (IgG) titres (values  $\geq 1.00$  as reactive) using VITROS® COVID-19 antibody tests.<sup>28</sup>

226 Adverse events were recorded from time of signature of informed consent and graded  
227 according to the Common Terminology Criteria for Adverse Events, version 5.0.<sup>29</sup> Causality  
228 was assessed by the investigators for any serious adverse events.

## 229 **Statistical Analysis**

230 Only 10 subjects were randomised and no formal sample estimation was done. Ct values and  
231 absolute copy numbers were compared using parametric, unpaired repeated t test with  
232 Welch's correction or non-parametric Mann Whitney U test. A two-tailed,  $p < 0.05$ , was  
233 considered statistically significant.

## 234 **Results**

235 All 10 participants were included for final analysis. All participants consented and were  
236 randomised within 2 days of their symptom onset. All patients allocated to treatment arm  
237 received their medications. Demographic and baseline clinical characteristics are summarized

238 in Table 1. 8/10 participants were female with a median (range) age of 27.5 (39, 25) years. In  
239 the control arm 3 patients did not have detectable viral RNA, when tested in the research lab.  
240 Table 2 shows changes that occurred over the follow up period. All treated participants  
241 showed rising Ct values from day 3. Difference in mean change in Ct values for the Rd/Rp &  
242 N genes, between treated and control group, was 16.41 (95% CI – 0.3527 to 32.48,  $p=0.047$ ,  
243 Welch's t test, two tailed). Difference in Ct values of E gene, 17.75 (95% CI;-0.1321 to  
244 35.63,  $p = 0.05$ , unpaired t test with Welch's correction, 2 tailed). Figures 2a & 2b show  
245 estimation plots for differences seen in Ct values. Figure 3 shows the change in copies/ $\mu$ L of  
246 the nucleocapsid (N1+N2) gene. A Mann Whitney test indicated that the drop in copy  
247 numbers among the treated participants was significant compared to the control group;  $U =$   
248 0.000,  $p<0.029$ . Individual patient wise change in absolute copy numbers is shown in  
249 supplementary figure panels.

250 rRT-PCR testing done in the clinic on day 1, 7, and 14 and had 3 participants (60%) turn  
251 negative by day 7 and all turned negative by day 14 and stayed negative until day 28. In the  
252 SoC group 2 participants had zero detectable viral loads at baseline, 2 participants tested  
253 negative on day 14, and the last participant tested remained positive on day 28.

254 None of the participants experienced any serious adverse event. One participant in the  
255 treatment arm had Grade 1 diarrheal episode (CTAE ver. 5.0). No intervention was need, but  
256 Prolectin-M was reduced to 5 tablets per day. All participants were fit for discharge on day  
257 14 and with no restrictions except for 2 subjects in the control arm, who tested positive even  
258 on day 14. No one had re admission when followed up at day 21 and 28.

## 259 **Discussion**

260 This is the first ever reported randomised controlled trial of a galectin antagonist against  
261 SARS-CoV-2. Blocking N terminal domain (NTD) of S1 subunit, present on spike protein, is

262 seen to have significantly lowered viral gene expression. All five participants in treatment  
263 group demonstrated a rapid drop by day 3 in copies/ $\mu$ L of Nucleocapsid protein gene.  
264 A higher Ct value correlates with lower risk of infectiousness, as reported from a cohort in  
265 England{ref}, There was rise in Ct >29, for genes, Rd/Rp, N and E genes in the treated  
266 group. However, participants in control group (001 & 007), remained potentially infective  
267 even on day 7 and day 14.

268 The detection of anti-spike protein IgG on day 28, is an expression of humoral response  
269 against the virus.<sup>30</sup> The N protein is highly immunogenic compared to the S protein and in the  
270 absence of glycosylation sites on it results in N-specific neutralizing antibody production  
271 early in the stage of acute infection. All participants in the active arm of the trial had a  
272 reactive IgG. This trial achieved its primary objective of demonstrating the effect of  
273 Prolectin-M on lowering viral infectiousness. The method used to recruit and randomize  
274 patients, enabled safe administration of the oral drug which demonstrated an ability to block  
275 viral replication.

276 Strengths of this study are randomisation, concealed allocation, and one hundred percent  
277 compliance to treatment, and all procedures in the protocol. There was no incidence of any  
278 serious adverse events. A higher cut off value for either cycle threshold or copy numbers on  
279 ddPCR as an eligibility criteria could have demonstrated a more significant treatment effect.  
280 Hence future trials will need to use either a pre-determined lower (<16) baseline Ct value or a  
281 higher copy number for ddPCR.

282 Galectin antagonists can potentially prevent SARS-CoV-2 entry into human cells.<sup>19</sup> A larger  
283 clinical trial will give us the evidence needed to understand its true clinical benefit. Due to  
284 the excellent safety profile of galectin antagonists, additional methods of delivery, such as an  
285 intravenous, or subcutaneous injection should be examined for a reduction in the number of  
286 systemically expressed copies of the virus. In addition, Prolectin-M could be very effective as

287 a prophylactic to stop the community spread of the disease. The results from this pilot and  
288 feasibility trial sets the stage for a definitive large randomised controlled clinical trial using  
289 polysaccharides as galectin antagonists in order to study their potential role as a Post  
290 Infection Immunisation (PII) which could lower the basic reproduction number (Ro) of the  
291 disease by lowering the levels of contagiousness and transmissibility.

292 Acknowledgements:

293 There are no acknowledgements to be mentioned.

294 Source of Funding: Pharmalectin Inc contracted the trial to a Contract Research Organisation  
295 – CIMED Life Sciences. Pharmalectin and CIMED had no role in data collection, analysis or  
296 interpretation of the results.

297 Conflict of Interest:

298 The corresponding author was the listed Principal Investigator for the trial at Narayana  
299 Hrudayalaya Limited and is the Group Head of Clinical Research. His department has  
300 received remuneration from the company – Pharmalectin Inc, towards conducting the clinical  
301 trials at the center.

302 David Platt is the CEO of Pharmalectin Inc. However he or his team did not have any access  
303 to the data, during the trial and after completion. They did not involve in the statistical  
304 analysis and only contributed as a co- author in this manuscript.

305 Other Co – authors have no specific conflict of interest to declare.

306

307

## References

- 1
- 2
- 3 1. Team W. Weekly update on COVID-19 - 23 October 2020. In. *Emergency Situation*
- 4 *Updates.* World Health Organization
- 5 2020:[https://www.who.int/publications/m/item/weekly-update-on-covid-19---23-](https://www.who.int/publications/m/item/weekly-update-on-covid-19---23-october)
- 6 [october.](https://www.who.int/publications/m/item/weekly-update-on-covid-19---23-october)
- 7 2. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for
- 8 Coronavirus Disease 2019 (COVID-19): A Review. *JAMA.* 2020;323(18):1824-1836
- 9 % @ 0098-7484.
- 10 3. Wevers BA, van der Hoek L. Recently discovered human coronaviruses. *Clin Lab*
- 11 *Med.* 2009;29(4):715-724.
- 12 4. Gallagher TM, Buchmeier MJ. Coronavirus spike proteins in viral entry and
- 13 pathogenesis. *Virology.* 2001;279(2):371-374.
- 14 5. Huang Y, Yang C, Xu X-f, Xu W, Liu S-w. Structural and functional properties of
- 15 SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19.
- 16 *Acta Pharmacologica Sinica.* 2020;41(9):1141-1149.
- 17 6. Bertram S, Dijkman R, Habjan M, et al. TMPRSS2 activates the human coronavirus
- 18 229E for cathepsin-independent host cell entry and is expressed in viral target cells in
- 19 the respiratory epithelium. *J Virol.* 2013;87(11):6150-6160.
- 20 7. Fantini J, Di Scala C, Chahinian H, Yahi N. Structural and molecular modelling
- 21 studies reveal a new mechanism of action of chloroquine and hydroxychloroquine
- 22 against SARS-CoV-2 infection. *Int J Antimicrob Agents.* 2020;55(5):105960.
- 23 8. Wang Q, Zhang Y, Wu L, et al. Structural and Functional Basis of SARS-CoV-2
- 24 Entry by Using Human ACE2. *Cell.* 2020;181(4):894-904.e899.
- 25 9. Li F. Structure, Function, and Evolution of Coronavirus Spike Proteins. *Annu Rev*
- 26 *Virol.* 2016;3(1):237-261.
- 27 10. Johannes L, Jacob R, Leffler H. Galectins at a glance. *Journal of Cell Science.*
- 28 2018;131(9):jcs208884.
- 29 11. Vasta GR. Roles of galectins in infection. *Nature Reviews Microbiology.*
- 30 2009;7(6):424-438.
- 31 12. Miller MC, Zheng Y, Yan J, Zhou Y, Tai G, Mayo KH. Novel polysaccharide binding
- 32 to the N-terminal tail of galectin-3 is likely modulated by proline isomerization.
- 33 *Glycobiology.* 2017;27(11):1038-1051.
- 34 13. Dong R, Zhang M, Hu Q, et al. Galectin-3 as a novel biomarker for disease diagnosis
- 35 and a target for therapy (Review). *Int J Mol Med.* 2018;41(2):599-614.
- 36 14. Rodriguez FJ, Scheithauer BW, Roncaroli F, et al. Galectin-3 Expression is
- 37 Ubiquitous in Tumors of the Sellar Region, Nervous System, and Mimics: An
- 38 Immunohistochemical and RT-PCR Study. *The American Journal of Surgical*
- 39 *Pathology.* 2008;32(9):1344-1352.
- 40 15. La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load as determined by cell
- 41 culture as a management tool for discharge of SARS-CoV-2 patients from infectious
- 42 disease wards. *Eur J Clin Microbiol Infect Dis.* 2020;39(6):1059-1061.
- 43 16. Jefferson T, Spencer E, Brassey J, Heneghan C. Viral cultures for COVID-19
- 44 infectivity assessment. Systematic review. *medRxiv.* 2020:2020.2008.2004.20167932.
- 45 17. Colton H, Ankcorn M, Yavuz M, et al. Improved sensitivity using a dual target, E and
- 46 RdRp assay for the diagnosis of SARS-CoV-2 infection: Experience at a large NHS
- 47 Foundation Trust in the UK. *J Infect.* 2020:S0163-4453(0120)30339-X.
- 48 18. Falzone L, Musso N, Gattuso G, et al. Sensitivity assessment of droplet digital PCR
- 49 for SARS-CoV-2 detection. *Int J Mol Med.* 2020;46(3):957-964.

- 1 19. Caniglia JL, Guda MR, Asuthkar S, Tsung AJ, Velpula KK. A potential role for  
2 Galectin-3 inhibitors in the treatment of COVID-19. *PeerJ*. 2020;8:e9392.
- 3 20. Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 Infections  
4 and Transmission in a Skilled Nursing Facility. *N Engl J Med*. 2020;382(22):2081-  
5 2090.
- 6 21. Gandhi M, Yokoe DS, Havlir DV. Asymptomatic Transmission, the Achilles' Heel of  
7 Current Strategies to Control Covid-19. *N Engl J Med*. 2020;382(22):2158-2160.
- 8 22. Singanayagam A, Patel M, Charlett A, et al. Duration of infectiousness and  
9 correlation with RT-PCR cycle threshold values in cases of COVID-19, England,  
10 January to May 2020. *Euro Surveill*. 2020;25(32):2001483.
- 11 23. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an  
12 international community of software platform partners. *Journal of Biomedical  
13 Informatics*. 2019;95:103208.
- 14 24. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic  
15 data capture (REDCap)—A metadata-driven methodology and workflow process for  
16 providing translational research informatics support. *Journal of Biomedical  
17 Informatics*. 2009;42(2):377-381.
- 18 25. Eldridge SM, Chan CL, Campbell MJ, et al. CONSORT 2010 statement: extension to  
19 randomized pilot and feasibility trials. *Pilot Feasibility Stud*. 2016;2:64-64.
- 20 26. Yinon M Bar-On AF, Rob Phillips, Ron Milo. SARS-CoV-2 (COVID-19) by the  
21 numbers. In. *eLife*. <https://elifesciences.org/articles/57309>: eLife 2020;9:e57309;  
22 2020.
- 23 27. Edros RZ, McDonnell S, Al-Rubeai M. Using Molecular Markers to Characterize  
24 Productivity in Chinese Hamster Ovary Cell Lines. *PLoS One*. 2013;8(10):e75935.
- 25 28. Garnett E, Jung J, Tam E, et al. Clinical validation and performance evaluation of the  
26 automated Vitros Total Anti-SARS-CoV-2 Antibodies assay for screening of  
27 serostatus in COVID-19. *medRxiv*. 2020:2020.2006.2009.20126474.
- 28 29. Diane MF Savarese M. Common Terminology Criteria for Adverse Events (CTCAE).  
29 [https://ctep.cancer.gov/protocoldevelopment/electronic\\_applications/ctc.htm](https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm).  
30 Published 2017. Accessed.
- 31 30. Wang Y, Chang Z, Ouyang J, et al. Profiles of IgG antibodies to nucleocapsid and  
32 spike proteins of the SARS-associated coronavirus in SARS patients. *DNA Cell Biol*.  
33 2005;24(8):521-527.  
34

1 **Table 1 – Baseline characteristics**

2

Characteristic	Treated	Control
Number	5	5
Age	28.4 ± 3.195	29.1 ± 4.53
Sex (female)	4	4
rRT PCR confirmed Sars-CoV-2 infection	5	5
Time from symptom onset to randomization (median)	1.80 days	2 days
WHO – CPS Score (0-10) = 4	Score 2 (5)	Score 2 (5)
7-point ordinal scale	3	3
Co – existing conditions	Nil	Nil
Laboratory Values		
CRP, mg/L	1.13 ± 0.80	4.93 ± 6.54
D – Dimer, µg/L	84.8 ± 78.25	95.60 ± 83.73
Neutrophil Count	63±15.24	53.82±9.19
Lymphocyte count	28.89±10.69	33.78±6.60
Lymphocytes to neutrophil ratio	0.691±0.557	0.617±0.17
Lymphocyte to monocyte ratio	0.41±0.91	0.38±0.23
RDW	14.58±1.90	16.69±2.89
Hemoglobin	13.24 ±0.20	12.27±0.87
Platelet count	227±67.32	266.6±109.78
ALT/ SGPT	19 ± 8.98	16 ± 5.33
AST / SGOT	29 ± 8.04	25.6 ± 3.43
Creatinine	0.66 ± 0.11	0.85 ± 0.26
Ferritin	27.96 ± 36.69	13.30 ± 7.47
LDH	219 ± 39.96	197 ± 3 6.63
Cycle thresholds	N = 5	N = 2
Rd/Rp + Nucleocapsid Gene	21.306	19.549
Envelope Gene	23.126	22.0895




1 **Table 2: Follow up, changes seen after randomization**

2


Characteristics	N	Treated	N	Control	Difference between two groups
Change from Baseline SARS-CoV-2 status, Day 7	5	3/ 5 (60%) negative	5	No change	Yes
Day 28 - Serum Ig G (Reactive)	5	All 5 Reactive)	5	3 (Reactive) 2 (Non-Reactive)	Yes
Reactive ( $\geq 1.00$ ) Serum IgG antibody titres on day 28 Median (IQR)	5	9.08 (8.68, 10.1)	3	4.58 (0.00, 5.68)	Yes
Change in 7- point ordinal scale day 14	5	All scored 1	5	3 scored 1 2 scored 2 restricted as they were positive	Yes
Change in 7- point ordinal scale day 21	5	No change from last assessment	5	Yes – 2 to 1	No
Change in 7- point ordinal scale day 28	5	No change from last assessment	5	No change from last assessment	No
Cycle Threshold on day 7 – mean increase from baseline					
Rd/Rp + Nucleocapsid Gene	5	+ 25.86	5	+ 9.446	Yes, 16.41 95% CI – 0.3527 to 32.48, p=0.047
Envelope Gene	5	+ 28.27	5	+ 10.52	Yes, 17.75 95% CI;-0.1321 to 35.63, p = 0.05

1



2  
3  
4  
5  
6


Figure 2 a – Change in Ct values over time – Rd/Rp+N gene



7  
8  
9  
10  
11  
12

Figure 2 b – Change in Ct value over time – Envelope Gene


1  
2  
3



4  
5  
6

Figure 3 – drop in absolute copy numbers of nucleocapsid gene over time – Treated group

1




2


3

4 Figure 4 – difference in IgG on day 28


5




Supplementary Figure 1 (a – e) Nucleocapsid gene expression in Treated group participant



Supplementary Figure 2– Nucleocapsid gene expression in Control group participants



Supplementary Figure 1 (a – e) Nucleocapsid gene expression in Treated group participant



Supplementary Figure 2– Nucleocapsid gene expression in Control group participants